REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.24 +1.97%

+$0.16 today

Market cap
$478.73M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.96M

Average 1.24M

Returns on capital

REGENXBIO Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-188.7%

avg -47.1%

ROIC

-42.1%

avg -28.4%

ROA

-42.8%

avg -23.6%

Analysis

ROIC is currently the strongest return metric at -42.1% versus its period average of -28.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Curran Simpson

President, Chief Executive Officer & DirectorUSD 1.07M64338.05K0.65%

Patrick J. Christmas

Executive Vice President & Chief Strategy and Legal OfficerUSD 944.7K55240.69K0.47%

Stephen Pakola

Executive Vice President & Chief Medical OfficerUSD 784.97K57——

Olivier Danos

Executive Vice President & Chief Scientific OfficerUSD 770.12K68226.35K0.44%

Mitchell Chan

Executive Vice President & Chief Financial OfficerUSD 205.31K45147.12K0.28%

Shiva G. Fritsch

Chief Communications & People Officer————

Jahannaz Dastgir

Clinical Development Lead————

Ram Palanki

Executive Vice President & Chief Commercial Officer—50——

Craig Malzahn

Executive Vice President of Product Development & Chief Technology Officer—53109.74K0.21%

Nina Hunter

SVP of Global Regulatory Strategy and Quality————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$949,381.45

Sells

5

$939,970.44

Net Transaction Value

+$9,411.01

Net buying

Most Active

PAKOLA STEVE

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 27, 26

Ciongoli Gregory Austin

Direct

Buy$499.7K
Aug 26, 26

Ciongoli Gregory Austin

Direct

Buy$449.7K
Jul 2, 26

PAKOLA STEVE

Direct

Sell$29.5K
Jul 1, 26

PAKOLA STEVE

Direct

Sell$472.3K
Jun 29, 26

PAKOLA STEVE

Direct

Sell$216.5K
May 11, 26

PAKOLA STEVE

Direct

Sell$168.7K
Mar 10, 26

PAKOLA STEVE

Direct

Sell$53K

Summary

Insiders reported 2 buys worth $949,381.45 and 5 sells worth $939,970.44 over the last 12 months. That adds up to net buying of $9,411.01. PAKOLA STEVE was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+14.8%
+36.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +14.8% over three years. Forward estimates point to Revenue at +36.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does REGENXBIO Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RGNX's management, answered from reported figures.

Who manages RGNX?

REGENXBIO Inc. (RGNX) lists 10 active executives. The top listed executive is Curran Simpson, President, Chief Executive Officer & Director.

Are RGNX insiders buying or selling?

Recent insider activity shows net buying of $25.15M.